Reference
·Primary source
Thai FDA Clinical Longevity Protocol Framework: Q1 2027 Effect Date
Compounding-pharmacy registration; off-label-by-protocol clinical use
The Ministry of Public Health Notification on Clinical Longevity and Compounded Therapy Protocols B.E. 2569 (2026), published December 2026 with effect January 2027, registers a whitelist of Thai FDA-approved compounding pharmacies authorised to prepare rapamycin, metformin, peptide and senolytic formulations for clinical longevity indications under physician-of-record protocols. The framework codifies the off-label prescribing pathway that the Thai Medical Council November 2024 guideline outlined, and creates a documented audit trail that satisfies inbound-buyer due diligence (Singapore Health Sciences Authority and Hong Kong Department of Health both accept the Thai framework as substantively equivalent for travel-medicine documentation purposes). The framework is the binding regulatory catalyst that distinguishes the 2027 segment from prior grey-market wellness-tourism volumes.
Figure in context
The Ministry of Public Health Notification on Clinical Longevity and Compounded Therapy Protocols B.E. 2569 (2026), published December 2026 with effect January 2027, registers a whitelist of Thai FDA-approved compounding pharmacies authorised to prepare rapamycin, metformin, peptide and senolytic formulations for clinical longevity indications under physician-of-record protocols. The framework codifies the off-label prescribing pathway that the Thai Medical Council November 2024 guideline outlined, and creates a documented audit trail that satisfies inbound-buyer due diligence (Singapore Health Sciences Authority and Hong Kong Department of Health both accept the Thai framework as substantively equivalent for travel-medicine documentation purposes). The framework is the binding regulatory catalyst that distinguishes the 2027 segment from prior grey-market wellness-tourism volumes.
The Ministry of Public Health Notification on Clinical Longevity and Compounded Therapy Protocols B.E. 2569 (2026), published December 2026 with effect January 2027, registers a whitelist of Thai FDA-approved compounding pharmacies authorised to prepare rapamycin, metformin, peptide and senolytic formulations for clinical longevity indications under physician-of-record protocols. The framework codifies the off-label prescribing pathway that the Thai Medical Council November 2024 guideline outlined, and creates a documented audit trail that satisfies inbound-buyer due diligence (Singapore Health Sciences Authority and Hong Kong Department of Health both accept the Thai framework as substantively equivalent for travel-medicine documentation purposes). The framework is the binding regulatory catalyst that distinguishes the 2027 segment from prior grey-market wellness-tourism volumes.
Time scope
Effective Q1 2027
Source basis
Primary source
Interpretation notes
What this tells you
The Ministry of Public Health Notification on Clinical Longevity and Compounded Therapy Protocols B.E. 2569 (2026), published December 2026 with effect January 2027, registers a whitelist of Thai FDA-approved compounding pharmacies authorised to prepare rapamycin, metformin, peptide and senolytic formulations for clinical longevity indications under physician-of-record protocols. The framework codifies the off-label prescribing pathway that the Thai Medical Council November 2024 guideline outlined, and creates a documented audit trail that satisfies inbound-buyer due diligence (Singapore Health Sciences Authority and Hong Kong Department of Health both accept the Thai framework as substantively equivalent for travel-medicine documentation purposes). The framework is the binding regulatory catalyst that distinguishes the 2027 segment from prior grey-market wellness-tourism volumes.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand Longevity-Medicine Clinic Tourism Market Size
Insight derivation from Bumrungrad Form 56-1 FY2024, BDMS Form 56-1 FY2024, TAT Medical Wellness Strategic Plan 2023-2027, IMARC Global Longevity 2024, retreat resort tariff disclosures
Thailand Longevity-Clinic 3-5 Day Package Average Selling Price
Bumrungrad VitalLife clinic tariff 2025, Samitivej Longevity Center programme menu 2025, BNH Wellness Center menu 2025, Bangkok Hospital Longevity Center brochure 2026
Phuket Wellness Resort 14-Day Longevity Retreat Average Selling Price
Banyan Tree Wellbeing Sanctuary tariff 2025, Aman Puri Wellness Immersion brochure 2025, Six Senses Yao Noi wellness menu 2025, Insight derivation
Thailand Longevity-Clinic Inbound Buyer Origin Mix
TCEB Wellness Tourism Report 2026 buyer-profile annex, Bumrungrad Form 56-1 FY2024 international-patient mix disclosure, Insight derivation
BOI Section 8 Medical-Tourism Premium Tier: 0% Duty on Longevity Equipment
Thailand Board of Investment A4 Guide 2024, BOI project approvals 2024-2026, Bumrungrad and BDMS investment disclosures
Genomics Thailand Cohort: 50,000-Person Whole-Genome Substrate for Clinical Longevity
NSTDA Genomics Thailand Initiative cohort progress report December 2025, Bumrungrad VitalLife genomic-medicine programme materials
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.